Fig. 1: Isatuximab monotherapy treatment response correlation with CD38 receptor density.

A Swimmer plot of time on treatment with isatuximab monotherapy. Each bar represents one of the 31 patients evaluable for response in the study (i.e., patients who completed at least one cycle of treatment and who had at least one disease assessment or patients with clinical progression or patients who died within 30 days of first dose due to disease progression). One out of the 31 patients had no evaluable response. Text in red font corresponds to the reason for treatment discontinuation. B Higher baseline CD38 receptor density was associated with longer periods from the last daratumumab dose to the CD38 receptor density assessment date. The scatter plot shows the CD38 receptor density data and time from last daratumumab dose to CD38 receptor density assessment date (all-treated population). The CD38 receptor density of cancer cells was measured at baseline by quantitative flow cytometry in bone marrow aspirate from 19 of 32 patients. The estimated CD38 receptor density reflects the number of free receptors per cell accessible for isatuximab binding and not the total CD38 receptor density. BOR best overall response, MR minimal response, NE not evaluable, PD progressive disease, QW/Q2W once weekly for 4 weeks, then every other week, SD stable disease.